The neonatal sepsis programme was launched in 2017 with two target product profiles to guide development of improved antibiotic treatment for drug-resistant sepsis in babies. GARDP’s first partnership agreement was signed with Entasis Therapeutics to co-develop zoliflodacin, a novel first-in-class oral antibiotic to address the rapidly growing threat of drug-resistant gonorrhoea. GARDP has also developed a programme to recover and share experts´ knowledge to speed up antibiotic drug discovery and build a long-term portfolio.
On 4th September 2017, Germany together with a number of countries, pledged EUR 56.5 million during a fundraising event for GARDP hosted in Berlin by the German Federal Ministry of Health and the German Federal Ministry of Education and Research. Contributions were made by the Netherlands, Switzerland, South Africa, the Wellcome Trust, Luxembourg, the United Kingdom and Germany. This is an important step for GARDP in order to support the implementation of GARDP’s business plan and its R&D programmes. Learn more about the pledging event: gardp.org/pledging
GARDP has finalized its first seven-year business plan, which outlines the overall R&D strategy, prioritization process, and sustainable access approach, and notably serves as a roadmap for its concrete R&D programmes for the coming years. An official Scientific Advisory Committee (SAC) has now been approved by the DNDi Board of Directors (GARDP’s governing body). This committee of experts in drug-resistant infections and in drug discovery and development advises on GARDP programmes and projects.
GARDP has, within its first 8 months, built up a team of 10 people with additional support staff from DNDi contributing directly to GARDP programmes.